424 related articles for article (PubMed ID: 26539795)
21. Targeting MYCN and ALK in resistant and relapsing neuroblastoma.
Tucker ER; Poon E; Chesler L
Cancer Drug Resist; 2019; 2(3):803-812. PubMed ID: 35582571
[TBL] [Abstract][Full Text] [Related]
22. Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma.
Inandiklioğlu N; Yilmaz S; Demirhan O; Erdoğan S; Tanyeli A
Asian Pac J Cancer Prev; 2012; 13(11):5391-7. PubMed ID: 23317189
[TBL] [Abstract][Full Text] [Related]
23. Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.
Fransson S; Hansson M; Ruuth K; Djos A; Berbegall A; Javanmardi N; Abrahamsson J; Palmer RH; Noguera R; Hallberg B; Kogner P; Martinsson T
Genes Chromosomes Cancer; 2015 Feb; 54(2):99-109. PubMed ID: 25251827
[TBL] [Abstract][Full Text] [Related]
24. Neuroblastoma.
Nakagawara A; Li Y; Izumi H; Muramori K; Inada H; Nishi M
Jpn J Clin Oncol; 2018 Mar; 48(3):214-241. PubMed ID: 29378002
[TBL] [Abstract][Full Text] [Related]
25. Two siblings with familial neuroblastoma with distinct clinical phenotypes harboring an ALK germline mutation.
Kudo K; Ueno H; Sato T; Kubo K; Kanezaki R; Kobayashi A; Kamio T; Sasaki S; Terui K; Kurose A; Yoshida K; Shiozawa Y; Toki T; Ogawa S; Ito E
Genes Chromosomes Cancer; 2018 Dec; 57(12):665-669. PubMed ID: 30350464
[TBL] [Abstract][Full Text] [Related]
26. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
[TBL] [Abstract][Full Text] [Related]
27. Genetic susceptibility to neuroblastoma: current knowledge and future directions.
Ritenour LE; Randall MP; Bosse KR; Diskin SJ
Cell Tissue Res; 2018 May; 372(2):287-307. PubMed ID: 29589100
[TBL] [Abstract][Full Text] [Related]
28. Oncogenic mutations of ALK in neuroblastoma.
Ogawa S; Takita J; Sanada M; Hayashi Y
Cancer Sci; 2011 Feb; 102(2):302-8. PubMed ID: 21205076
[TBL] [Abstract][Full Text] [Related]
29. Recent insights into the biology of neuroblastoma.
Schleiermacher G; Janoueix-Lerosey I; Delattre O
Int J Cancer; 2014 Nov; 135(10):2249-61. PubMed ID: 25124476
[TBL] [Abstract][Full Text] [Related]
30. Neuroblastoma: A Tough Nut to Crack.
Speleman F; Park JR; Henderson TO
Am Soc Clin Oncol Educ Book; 2016; 35():e548-57. PubMed ID: 27249766
[TBL] [Abstract][Full Text] [Related]
31. Neuroblastoma models for insights into tumorigenesis and new therapies.
Kiyonari S; Kadomatsu K
Expert Opin Drug Discov; 2015 Jan; 10(1):53-62. PubMed ID: 25345447
[TBL] [Abstract][Full Text] [Related]
32. Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.
Cao Y; Jin Y; Yu J; Wang J; Qiu Y; Duan X; Ye Y; Cheng Y; Dong L; Feng X; Wang D; Li Z; Tian X; Wang H; Yan J; Zhao Q
Oncotarget; 2017 Jul; 8(30):49689-49701. PubMed ID: 28591696
[TBL] [Abstract][Full Text] [Related]
33. Childhood tumors of the nervous system as disorders of normal development.
Grimmer MR; Weiss WA
Curr Opin Pediatr; 2006 Dec; 18(6):634-8. PubMed ID: 17099362
[TBL] [Abstract][Full Text] [Related]
34. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma.
Schulte JH; Bachmann HS; Brockmeyer B; Depreter K; Oberthür A; Ackermann S; Kahlert Y; Pajtler K; Theissen J; Westermann F; Vandesompele J; Speleman F; Berthold F; Eggert A; Brors B; Hero B; Schramm A; Fischer M
Clin Cancer Res; 2011 Aug; 17(15):5082-92. PubMed ID: 21632861
[TBL] [Abstract][Full Text] [Related]
35. Targeted expression of MYCN causes neuroblastoma in transgenic mice.
Weiss WA; Aldape K; Mohapatra G; Feuerstein BG; Bishop JM
EMBO J; 1997 Jun; 16(11):2985-95. PubMed ID: 9214616
[TBL] [Abstract][Full Text] [Related]
36. ARID1B alterations identify aggressive tumors in neuroblastoma.
Lee SH; Kim JS; Zheng S; Huse JT; Bae JS; Lee JW; Yoo KH; Koo HH; Kyung S; Park WY; Sung KW
Oncotarget; 2017 Jul; 8(28):45943-45950. PubMed ID: 28521285
[TBL] [Abstract][Full Text] [Related]
37. Nervous system: Embryonal tumors: Neuroblastoma.
Pudela C; Balyasny S; Applebaum MA
Atlas Genet Cytogenet Oncol Haematol; 2020 Jul; 24(7):284-290. PubMed ID: 32296467
[TBL] [Abstract][Full Text] [Related]
38. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number.
Wang Q; Diskin S; Rappaport E; Attiyeh E; Mosse Y; Shue D; Seiser E; Jagannathan J; Shusterman S; Bansal M; Khazi D; Winter C; Okawa E; Grant G; Cnaan A; Zhao H; Cheung NK; Gerald W; London W; Matthay KK; Brodeur GM; Maris JM
Cancer Res; 2006 Jun; 66(12):6050-62. PubMed ID: 16778177
[TBL] [Abstract][Full Text] [Related]
39. ALK pERKs up MYCN in neuroblastoma.
Lindner S; Henssen A; Astrahantseff K; Schulte JH
Sci Signal; 2014 Oct; 7(349):pe27. PubMed ID: 25351246
[TBL] [Abstract][Full Text] [Related]
40. Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
Peifer M; Hertwig F; Roels F; Dreidax D; Gartlgruber M; Menon R; Krämer A; Roncaioli JL; Sand F; Heuckmann JM; Ikram F; Schmidt R; Ackermann S; Engesser A; Kahlert Y; Vogel W; Altmüller J; Nürnberg P; Thierry-Mieg J; Thierry-Mieg D; Mariappan A; Heynck S; Mariotti E; Henrich KO; Gloeckner C; Bosco G; Leuschner I; Schweiger MR; Savelyeva L; Watkins SC; Shao C; Bell E; Höfer T; Achter V; Lang U; Theissen J; Volland R; Saadati M; Eggert A; de Wilde B; Berthold F; Peng Z; Zhao C; Shi L; Ortmann M; Büttner R; Perner S; Hero B; Schramm A; Schulte JH; Herrmann C; O'Sullivan RJ; Westermann F; Thomas RK; Fischer M
Nature; 2015 Oct; 526(7575):700-4. PubMed ID: 26466568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
